{"id":"licensed-tiv-hd1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5614098","moleculeType":null,"molecularWeight":"533.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a high-dose formulation of the seasonal trivalent inactivated influenza vaccine (TIV), TIV-HD1 contains increased antigen content compared to standard-dose vaccines, intended to elicit a stronger and more robust immune response. This enhanced immunogenicity is particularly aimed at improving protection in populations with weaker immune responses, such as elderly individuals. The vaccine works by stimulating both humoral and cellular immunity against the three included influenza virus strains (typically two A subtypes and one B lineage).","oneSentence":"TIV-HD1 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against three influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:52.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults, particularly elderly populations"}]},"trialDetails":[{"nctId":"NCT03282240","phase":"PHASE3","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-08","conditions":"Influenza","enrollment":2670},{"nctId":"NCT02553343","phase":"PHASE2","title":"A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":792}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["High-dose trivalent influenza vaccine"],"phase":"phase_3","status":"active","brandName":"Licensed TIV-HD1","genericName":"Licensed TIV-HD1","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi-pasteur-a-sanofi-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"TIV-HD1 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against three influenza virus strains. Used for Seasonal influenza prevention in adults, particularly elderly populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}